Bulk Manufacturer of Controlled Substances Application: Noramco, 77108-77109 [2023-24613]
Download as PDF
<![CDATA[
77108
Federal Register / Vol. 88, No. 215 / Wednesday, November 8, 2023 / Notices
Sunshine Act, 5 U.S.C. 552(b). In
accordance with Commission policy,
subject matter listed above, not disposed
of at the scheduled meeting, may be
carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: November 6, 2023.
Sharon Bellamy,
Supervisory Hearings and Information
Officer.
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on October 4, 2023,
Noramco, 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
[FR Doc. 2023–24812 Filed 11–6–23; 11:15 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Controlled
substance
Drug Enforcement Administration
[Docket No. DEA–1287]
Importer of Controlled Substances
Application: Noramco
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Noramco has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before December 8, 2023. Such
persons may also file a written request
for a hearing on the application on or
before December 8, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
lotter on DSK11XQN23PROD with NOTICES1
DATES:
VerDate Sep<11>2014
16:54 Nov 07, 2023
Jkt 262001
Gamma Hydroxybutyric
Acid.
Marihuana .......................
Tetrahydrocannabinols ...
Nabilone .........................
Phenylacetone ................
Opium, Raw ....................
Opium Extracts ...............
Opium Fluid Extract ........
Opium Tincture ...............
Opium Powdered ............
Opium Granulated ..........
Opium Poppy/Poppy
Straw.
Noroxymorphone ............
Poppy Straw Concentrate.
Tapentadol ......................
Drug
code
Schedule
2010
I
7360
7370
7379
8501
9600
9610
9620
9630
9639
9640
9650
I
I
II
II
II
II
II
II
II
II
II
9668
9670
II
II
9780
II
The company plans to import
Phenylacetone (8501), and Poppy Straw
Concentrate (9670) to bulk manufacture
other controlled substances for
distribution to its customers. The
company plans to import an
intermediate form of Tapentadol (9780)
to bulk manufacture Tapentadol for
distribution to its customers. In
reference to drug codes 7360
(Marihuana) and 7370
(Tetrahydrocannabinols), the company
plans to import a synthetic cannabidiol
and a synthetic Tetrahydrocannabinol.
No other activity for these drug codes is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–24614 Filed 11–7–23; 8:45 am]
BILLING CODE P
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1286]
Bulk Manufacturer of Controlled
Substances Application: Noramco
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Noramco has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before January 8, 2024. Such
persons may also file a written request
for a hearing on the application on or
before January 8, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on October 04, 2023,
Noramco, 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUMMARY:
Controlled
substance
Gamma Hydroxybutyric
Acid.
Marihuana .......................
Tetrahydrocannabinols ...
Codeine-N-oxide .............
Dihydromorphine ............
Hydromorphinol ..............
Morphine-N-oxide ...........
Amphetamine .................
Lisdexamfetamine ..........
Methylphenidate .............
E:\FR\FM\08NON1.SGM
08NON1
Drug
code
Schedule
2010
I
7360
7370
9053
9145
9301
9307
1100
1205
1724
I
I
I
I
I
I
II
II
II
Federal Register / Vol. 88, No. 215 / Wednesday, November 8, 2023 / Notices
Controlled
substance
Nabilone .........................
Phenylacetone ................
Codeine ..........................
Dihydrocodeine ...............
Oxycodone .....................
Hydromorphone ..............
Hydrocodone ..................
Morphine .........................
Oripavine ........................
Thebaine .........................
Opium extracts ...............
Opium fluid extract .........
Opium, tincture ...............
Opium, powdered ...........
Opium, granulated ..........
Oxymorphone .................
Noroxymorphone ............
Tapentadol ......................
Drug
code
Schedule
7379
8501
9050
9120
9143
9150
9193
9300
9330
9333
9610
9620
9630
9639
9640
9652
9668
9780
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances as an Active Pharmaceutical
Ingredient for supply to its customers.
In reference to drug codes 7360
(Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–24613 Filed 11–7–23; 8:45 am]
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on August 3, 2023, Curia
Missouri Inc., 2460 West Bennett Street,
Springfield, Missouri 65807–1229,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
Controlled
substance
Gamma Hydroxybutyric
Acid.
Amphetamine .................
Lisdexamfetamine ..........
Methylphenidate .............
Phenylacetone ................
Tapentadol ......................
Drug
code
Schedule
2010
I
1100
1205
1724
8501
9780
II
II
II
II
II
BILLING CODE P
The company plans to bulk
manufacture the listed controlled
substances for internal use
intermediates or for sale to its
customers. No other activities for these
drug codes are authorized for this
registration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1291]
Bulk Manufacturer of Controlled
Substances Application: Curia
Missouri, Inc.
Claude Redd,
Acting Deputy Assistant Administrator.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
[FR Doc. 2023–24615 Filed 11–7–23; 8:45 am]
Curia Missouri Inc. has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before January 8, 2024. Such
persons may also file a written request
for a hearing on the application on or
before January 8, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
DEPARTMENT OF LABOR
AGENCY:
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
16:54 Nov 07, 2023
Jkt 262001
BILLING CODE P
Employee Benefits Security
Administration
220th Meeting of the Advisory Council
on Employee Welfare and Pension
Benefit Plans; Notice of Meeting
Pursuant to the authority contained in
section 512 of the Employee Retirement
Income Security Act of 1974 (ERISA), 29
U.S.C. 1142, the 220th open meeting of
the Advisory Council on Employee
Welfare and Pension Benefit Plans (also
known as the ERISA Advisory Council)
will be held on December 11–12, 2023.
On Monday, December 11, 2023, the
meeting will begin at 1:00 p.m. and end
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
77109
at approximately 4:30 p.m. (ET). On
Tuesday, December 12, 2023, the
meeting will begin at 8:30 a.m. and end
at approximately 3:00 p.m. (ET), with a
break for lunch.
The meeting will take place at the
U.S. Department of Labor, 200
Constitution Avenue NW, Washington,
DC 20210 in Room 6, C5320. The
meeting will also be accessible via
videoconference and some participants,
as well as members of the public, may
elect to attend virtually. Instructions for
public videoconference access will be
available on the ERISA Advisory
Council’s web page at https://
www.dol.gov/agencies/ebsa/about-ebsa/
about-us/erisa-advisory-council
approximately one week prior to the
meeting.
The purpose of the open meeting is
for Advisory Council members to
finalize their observations and
recommendations on the issues they
studied in 2023, present their
observations and recommendations to
the Department of Labor, and receive an
update from leadership of the Employee
Benefits Security Administration
(EBSA).
The issues studied by the ERISA
Advisory Council in 2023 are: (1) LongTerm Disability Benefits and Mental
Health Disparity, and (2) Recordkeeping
in the Electronic Age. Descriptions of
these topics are available on the ERISA
Advisory Council’s web page at https://
www.dol.gov/agencies/ebsa/about-ebsa/
about-us/erisa-advisory-council.
Organizations or members of the
public wishing to submit a written
statement may do so on or before
Monday, December 4, 2023, to Christine
Donahue, Executive Secretary, ERISA
Advisory Council. Statements should be
transmitted electronically as an email
attachment in text or pdf format to
donahue.christine@dol.gov. Statements
transmitted electronically that are
included in the body of the email will
not be accepted. Relevant statements
received on or before Monday,
December 4, 2023, will be included in
the record of the meeting and made
available through the EBSA Public
Disclosure Room. No deletions,
modifications, or redactions will be
made to the statements received as they
are public records. Warning: Do not
include any personally identifiable or
confidential business information that
you do not want publicly disclosed.
Individuals or representatives of
organizations interested in addressing
the ERISA Advisory Council at the
public meeting must submit a written
request to the Executive Secretary on or
before Monday, December 4, 2023, via
email to donahue.christine@dol.gov.
E:\FR\FM\08NON1.SGM
08NON1
]]>Agencies
[Federal Register Volume 88, Number 215 (Wednesday, November 8, 2023)]
[Notices]
[Pages 77108-77109]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24613]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1286]
Bulk Manufacturer of Controlled Substances Application: Noramco
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Noramco has applied to be registered as a bulk manufacturer of
basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
January 8, 2024. Such persons may also file a written request for a
hearing on the application on or before January 8, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on October 04, 2023, Noramco, 500 Swedes Landing Road,
Wilmington, Delaware 19801-4417, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
Marihuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
Codeine-N-oxide........................ 9053 I
Dihydromorphine........................ 9145 I
Hydromorphinol......................... 9301 I
Morphine-N-oxide....................... 9307 I
Amphetamine............................ 1100 II
Lisdexamfetamine....................... 1205 II
Methylphenidate........................ 1724 II
[[Page 77109]]
Nabilone............................... 7379 II
Phenylacetone.......................... 8501 II
Codeine................................ 9050 II
Dihydrocodeine......................... 9120 II
Oxycodone.............................. 9143 II
Hydromorphone.......................... 9150 II
Hydrocodone............................ 9193 II
Morphine............................... 9300 II
Oripavine.............................. 9330 II
Thebaine............................... 9333 II
Opium extracts......................... 9610 II
Opium fluid extract.................... 9620 II
Opium, tincture........................ 9630 II
Opium, powdered........................ 9639 II
Opium, granulated...................... 9640 II
Oxymorphone............................ 9652 II
Noroxymorphone......................... 9668 II
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances as an Active Pharmaceutical Ingredient for supply to its
customers. In reference to drug codes 7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as synthetic. No other activities for these drug codes are
authorized for this registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-24613 Filed 11-7-23; 8:45 am]
BILLING CODE P
